Search for more clinical trials
Pemetrexed Disodium and Cisplatin With or Without Cediranib Maleate in Treating Patients With Malignant Pleural Mesothelioma
Conditions
Advanced Malignant Mesothelioma - Epithelioid Mesothelioma - Recurrent Malignant Mesothelioma - Sarcomatoid Mesothelioma
Conditions: official terms
Lung Neoplasms - Mesothelioma
Study Type
Interventional
Study Phase
Phase 1/Phase 2
Study Design
Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment
Intervention
Name: Cediranib Maleate
Type: Drug
Name: Cisplatin
Type: Drug
Name: Pemetrexed Disodium
Type: Drug
Name: Placebo
Type: Other
Overall Status
Recruiting
Summary
This randomized phase I/II trial is studying the side effects and best dose of cediranib maleate when given together with pemetrexed disodium and cisplatin and to see how well it works in treating patients with malignant pleural mesothelioma. Drugs used in chemotherapy, pemetrexed disodium and cisplatin, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Cediranib maleate may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth and by blocking blood flow to the tumor. Giving pemetrexed disodium and cisplatin together with cediranib maleate may kill more tumor cells.
Detailed Description
OBJECTIVES:
I. To establish the maximum tolerated dose and the recommended phase II dose of cediranib maleate in combination with pemetrexed disodium and cisplatin in patients with malignant pleural mesothelioma. (Phase I) II. To compare the progression-free survival of patients treated with pemetrexed disodium and cisplatin with vs without cediranib maleate. (Phase II) III. To compare the overall survival of patients treated with these regimens. (Phase II) IV. To assess the safety and toxicity profile of these regimens. V. To assess the response rate (confirmed and unconfirmed, complete and partial responses) and disease control rate (responsive or stable disease) using RECIST criteria and modified RECIST criteria for pleural tumors in a subset of patients with measurable disease. (Phase II) VI. To assess the rate of agreement between local and central pathology review of mesothelioma and its histologic subtypes. (Phase II) VII. To collect specimens for banking for use in future research studies. (Phase II)
OUTLINE: This is a multicenter, phase I dose-escalation study of cediranib maleate followed by a phase II randomized study. Patients enrolled in the phase II portion of the study are stratified according to Zubrod performance status (0-1 vs 2) and histologic subtype (epithelioid vs biphasic/sarcomatoid).
PHASE I: Patients receive pemetrexed disodium IV over 10 minutes and cisplatin IV over 2 hours on day 1 and oral cediranib maleate once daily on days 1-21. Treatment repeats every 21 days for 6 courses in the absence of disease progression or unacceptable toxicity. Patients then receive oral cediranib maleate alone once daily in the absence of disease progression or unacceptable toxicity.
PHASE II: Patients are randomized to 1 of 2 treatment arms.
ARM I: Patients receive pemetrexed disodium IV over 10 minutes and cisplatin IV over 2 hours on day 1 and oral cediranib maleate once daily at the maximum tolerated dose determined in phase I on days 1-21. Treatment repeats every 21 days for 6 courses in the absence of disease progression or unacceptable toxicity. Patients then receive oral cediranib maleate alone once daily in the absence of disease progression or unacceptable toxicity.
ARM II: Patients receive pemetrexed disodium and cisplatin as in arm I and oral placebo once daily on days 1-21. Treatment repeats every 21 days for 6 courses in the absence of disease progression or unacceptable toxicity. Patients then receive oral placebo alone once daily in the absence of disease progression or unacceptable toxicity.
After completion of study therapy, patients are followed up periodically for up to 3 years.
I. To establish the maximum tolerated dose and the recommended phase II dose of cediranib maleate in combination with pemetrexed disodium and cisplatin in patients with malignant pleural mesothelioma. (Phase I) II. To compare the progression-free survival of patients treated with pemetrexed disodium and cisplatin with vs without cediranib maleate. (Phase II) III. To compare the overall survival of patients treated with these regimens. (Phase II) IV. To assess the safety and toxicity profile of these regimens. V. To assess the response rate (confirmed and unconfirmed, complete and partial responses) and disease control rate (responsive or stable disease) using RECIST criteria and modified RECIST criteria for pleural tumors in a subset of patients with measurable disease. (Phase II) VI. To assess the rate of agreement between local and central pathology review of mesothelioma and its histologic subtypes. (Phase II) VII. To collect specimens for banking for use in future research studies. (Phase II)
OUTLINE: This is a multicenter, phase I dose-escalation study of cediranib maleate followed by a phase II randomized study. Patients enrolled in the phase II portion of the study are stratified according to Zubrod performance status (0-1 vs 2) and histologic subtype (epithelioid vs biphasic/sarcomatoid).
PHASE I: Patients receive pemetrexed disodium IV over 10 minutes and cisplatin IV over 2 hours on day 1 and oral cediranib maleate once daily on days 1-21. Treatment repeats every 21 days for 6 courses in the absence of disease progression or unacceptable toxicity. Patients then receive oral cediranib maleate alone once daily in the absence of disease progression or unacceptable toxicity.
PHASE II: Patients are randomized to 1 of 2 treatment arms.
ARM I: Patients receive pemetrexed disodium IV over 10 minutes and cisplatin IV over 2 hours on day 1 and oral cediranib maleate once daily at the maximum tolerated dose determined in phase I on days 1-21. Treatment repeats every 21 days for 6 courses in the absence of disease progression or unacceptable toxicity. Patients then receive oral cediranib maleate alone once daily in the absence of disease progression or unacceptable toxicity.
ARM II: Patients receive pemetrexed disodium and cisplatin as in arm I and oral placebo once daily on days 1-21. Treatment repeats every 21 days for 6 courses in the absence of disease progression or unacceptable toxicity. Patients then receive oral placebo alone once daily in the absence of disease progression or unacceptable toxicity.
After completion of study therapy, patients are followed up periodically for up to 3 years.
Criteria for eligibility
Healthy Volunteers: No
Maximum Age: N/A
Minimum Age: 18 Years
Gender: Both
Criteria: Inclusion Criteria:
- Histologically or cytologically confirmed malignant pleural mesothelioma
- Not planning to undergo surgical resection
- Patients must have measurable or non-measurable disease by both RECIST and modified RECIST criteria for pleural tumors as documented by CT scan; examinations for assessment of measurable disease must have been completed within 28 days prior to registration; examinations for assessment of non-measurable disease must have been performed within 42 days prior to registration; all disease must be assessed and documented on the RECIST 1.1 and Modified RECIST Baseline Tumor Assessment Form
- Zubrod performance status 0-2
- ANC ≥ 1,500/mm^3
- Platelet count ≥ 100,000/mm^3
- Hemoglobin ≥ 9.0 g/dL (transfusion allowed)
- Total bilirubin ≤ 1.5 times upper limit of normal (ULN)
- SGOT or SGPT ≤ 2.5 times ULN (≤ 5 times ULN if liver metastases are present)
- Serum creatinine ≤ 1.5 times ULN
- Creatinine clearance ≥ 60 mL/min
- Proteinuria ≤ +1 on 2 consecutive dipsticks taken ≥ 7 days apart
- Repeat urinalysis not required provided first urinalysis shows no protein
- Not pregnant or nursing
- Fertile patients must agree to use effective contraception
- Must be able to swallow oral medications
- No mean QTc > 500 msec (with Bazett correction) by ECG or other significant ECG abnormality
- No NYHA class III-IV congestive heart failure
- No clinically significant hemoptysis, defined as > 1 tablespoon of bright red blood, within the past year
- No known HIV infection
- No other malignancy within the past 5 years except for adequately treated basal cell or squamous cell skin cancer, in situ cervical cancer, or adequately treated stage I or II cancer from which the patient is currently in complete remission.
- No other concurrent chemotherapy, hormonal therapy, radiotherapy, immunotherapy or any other type of therapy for treatment of cancer
- No prior systemic therapy (chemotherapy or other biological therapy) for unresectable malignant pleural mesothelioma
- Prior systemicchemotherapy or biologic therapy as neoadjuvant or adjuvant therapy allowed provided disease has recurred and systemic therapy was completed > 6 months before study entry
- No prior therapy with any of the study drugs
- At least 28 days since prior surgery (e.g., pleurectomy, pleurodeses, thoracic or other major surgeries) and recovered
- At least 28 days since prior radiotherapy and recovered
- No concurrent medication that may markedly affect renal function (e.g., vancomycin, amphotericin, pentamidine)
- No concurrent drugs or biologics with proarrhythmic potential
- No concurrent major surgery
- Histologically or cytologically confirmed malignant pleural mesothelioma
- Not planning to undergo surgical resection
- Patients must have measurable or non-measurable disease by both RECIST and modified RECIST criteria for pleural tumors as documented by CT scan; examinations for assessment of measurable disease must have been completed within 28 days prior to registration; examinations for assessment of non-measurable disease must have been performed within 42 days prior to registration; all disease must be assessed and documented on the RECIST 1.1 and Modified RECIST Baseline Tumor Assessment Form
- Zubrod performance status 0-2
- ANC ≥ 1,500/mm^3
- Platelet count ≥ 100,000/mm^3
- Hemoglobin ≥ 9.0 g/dL (transfusion allowed)
- Total bilirubin ≤ 1.5 times upper limit of normal (ULN)
- SGOT or SGPT ≤ 2.5 times ULN (≤ 5 times ULN if liver metastases are present)
- Serum creatinine ≤ 1.5 times ULN
- Creatinine clearance ≥ 60 mL/min
- Proteinuria ≤ +1 on 2 consecutive dipsticks taken ≥ 7 days apart
- Repeat urinalysis not required provided first urinalysis shows no protein
- Not pregnant or nursing
- Fertile patients must agree to use effective contraception
- Must be able to swallow oral medications
- No mean QTc > 500 msec (with Bazett correction) by ECG or other significant ECG abnormality
- No NYHA class III-IV congestive heart failure
- No clinically significant hemoptysis, defined as > 1 tablespoon of bright red blood, within the past year
- No known HIV infection
- No other malignancy within the past 5 years except for adequately treated basal cell or squamous cell skin cancer, in situ cervical cancer, or adequately treated stage I or II cancer from which the patient is currently in complete remission.
- No other concurrent chemotherapy, hormonal therapy, radiotherapy, immunotherapy or any other type of therapy for treatment of cancer
- No prior systemic therapy (chemotherapy or other biological therapy) for unresectable malignant pleural mesothelioma
- Prior systemicchemotherapy or biologic therapy as neoadjuvant or adjuvant therapy allowed provided disease has recurred and systemic therapy was completed > 6 months before study entry
- No prior therapy with any of the study drugs
- At least 28 days since prior surgery (e.g., pleurectomy, pleurodeses, thoracic or other major surgeries) and recovered
- At least 28 days since prior radiotherapy and recovered
- No concurrent medication that may markedly affect renal function (e.g., vancomycin, amphotericin, pentamidine)
- No concurrent drugs or biologics with proarrhythmic potential
- No concurrent major surgery
Locations
Highlands Oncology Group-Rogers
Rogers, Arkansas, United States
Kaiser Permanente-Deer Valley Medical Center
Status: Recruiting
Contact: Joseph T. Beck - 800-381-6939
Antioch, California, United States
Providence Saint Joseph Medical Center/Disney Family Cancer Center
Status: Recruiting
Contact: Louis Fehrenbacher - 626-564-3455
Burbank, California, United States
Kaiser Permanente-Fremont
Status: Recruiting
Contact: Keith S. Lanier - 503-215-6412
Fremont, California, United States
Kaiser Permanente
Status: Recruiting
Contact: Louis Fehrenbacher - 626-564-3455
Fresno, California, United States
Los Angeles County-USC Medical Center
Status: Recruiting
Contact: Louis Fehrenbacher - 626-564-3455
Los Angeles, California, United States
USC / Norris Comprehensive Cancer Center
Status: Recruiting
Contact: Barbara J. Gitlitz - 323-865-0451
Los Angeles, California, United States
Kaiser Permanente-Modesto
Status: Recruiting
Contact: Barbara J. Gitlitz - 323-865-0451
Modesto, California, United States
Kaiser Permanente-Oakland
Status: Recruiting
Contact: Louis Fehrenbacher - 626-564-3455
Oakland, California, United States
UC Irvine Health/Chao Family Comprehensive Cancer Center
Status: Recruiting
Contact: Louis Fehrenbacher - 626-564-3455
Orange, California, United States
Kaiser Permanente-Redwood City
Status: Recruiting
Contact: Sai-Hong I. Ou - 877-827-8839 - ucstudy@uci.edu
Redwood City, California, United States
Kaiser Permanente-Richmond
Status: Recruiting
Contact: Louis Fehrenbacher - 626-564-3455
Richmond, California, United States
Kaiser Permanente-Roseville
Status: Recruiting
Contact: Louis Fehrenbacher - 626-564-3455
Roseville, California, United States
Kaiser Permanente - Sacramento
Status: Recruiting
Contact: Louis Fehrenbacher - 626-564-3455
Sacramento, California, United States
Kaiser Permanente-South Sacramento
Status: Recruiting
Contact: Louis Fehrenbacher - 626-564-3455
Sacramento, California, United States
University of California Davis Comprehensive Cancer Center
Status: Recruiting
Contact: Louis Fehrenbacher - 626-564-3455
Sacramento, California, United States
Kaiser Permanente-San Francisco
Status: Recruiting
Contact: Karen L. Kelly - 916-734-3089
San Francisco, California, United States
Kaiser Permanente-Santa Teresa-San Jose
Status: Recruiting
Contact: Louis Fehrenbacher - 626-564-3455
San Jose, California, United States
Kaiser Permanente San Leandro
Status: Recruiting
Contact: Louis Fehrenbacher - 626-564-3455
San Leandro, California, United States
Kaiser Permanente-San Rafael
Status: Recruiting
Contact: Louis Fehrenbacher - 626-564-3455
San Rafael, California, United States
Kaiser Permanente Medical Center - Santa Clara
Status: Recruiting
Contact: Louis Fehrenbacher - 626-564-3455
Santa Clara, California, United States
Kaiser Permanente-Santa Rosa
Status: Recruiting
Contact: Louis Fehrenbacher - 626-564-3455
Santa Rosa, California, United States
Kaiser Permanente-South San Francisco
Status: Recruiting
Contact: Louis Fehrenbacher - 626-564-3455
South San Francisco, California, United States
Kaiser Permanente-Stockton
Status: Recruiting
Contact: Louis Fehrenbacher - 626-564-3455
Stockton, California, United States
Kaiser Permanente Medical Center-Vacaville
Status: Recruiting
Contact: Louis Fehrenbacher - 626-564-3455
Vacaville, California, United States
Kaiser Permanente-Vallejo
Status: Recruiting
Contact: Louis Fehrenbacher - 626-564-3455
Vallejo, California, United States
Kaiser Permanente-Walnut Creek
Status: Recruiting
Contact: Louis Fehrenbacher - 626-564-3455
Walnut Creek, California, United States
Saint Francis Hospital and Medical Center
Status: Recruiting
Contact: Louis Fehrenbacher - 626-564-3455
Hartford, Connecticut, United States
UF Cancer Center at Orlando Health
Status: Recruiting
Contact: Philip J. Stella - 734-712-4673
Orlando, Florida, United States
Northeast Georgia Medical Center
Status: Recruiting
Contact: Tirrell T. Johnson - 321-841-7246 - CancerClinicalTrials@orlandohealth.com
Gainesville, Georgia, United States
Oncare Hawaii Inc-Pali Momi
Status: Terminated
Aiea, Hawaii, United States
Pali Momi Medical Center
Status: Withdrawn
Aiea, Hawaii, United States
Kaiser Permanente Moanalua Medical Center
Status: Withdrawn
Honolulu, Hawaii, United States
Kapiolani Medical Center for Women and Children
Status: Recruiting
Contact: Louis Fehrenbacher - 626-564-3455
Honolulu, Hawaii, United States
Kuakini Medical Center
Status: Withdrawn
Honolulu, Hawaii, United States
Oncare Hawaii Inc-Kuakini
Status: Withdrawn
Honolulu, Hawaii, United States
Oncare Hawaii Inc-POB II
Status: Withdrawn
Honolulu, Hawaii, United States
OnCare Hawaii-Liliha
Status: Withdrawn
Honolulu, Hawaii, United States
Queen's Medical Center
Status: Withdrawn
Honolulu, Hawaii, United States
Straub Clinic and Hospital
Status: Withdrawn
Honolulu, Hawaii, United States
University of Hawaii Cancer Center
Status: Withdrawn
Honolulu, Hawaii, United States
Castle Medical Center
Status: Withdrawn
Kailua, Hawaii, United States
Wilcox Memorial Hospital and Kauai Medical Clinic
Status: Withdrawn
Lihue, Hawaii, United States
Saint Alphonsus Cancer Care Center-Boise
Status: Withdrawn
Boise, Idaho, United States
Kootenai Medical Center
Status: Recruiting
Contact: Philip J. Stella - 734-712-4673
Coeur D'Alene, Idaho, United States
Kootenai Cancer Center
Status: Recruiting
Contact: Benjamin T. Marchello - 800-648-6274
Post Falls, Idaho, United States
Kootenai Cancer
Status: Recruiting
Contact: Benjamin T. Marchello - 800-648-6274
Sandpoint, Idaho, United States
Illinois CancerCare-Bloomington
Status: Recruiting
Contact: Benjamin T. Marchello - 800-648-6274
Bloomington, Illinois, United States
Saint Joseph Medical Center
Status: Recruiting
Contact: James L. Wade - 217-876-4740 - kcheek@dmhhs.org
Bloomington, Illinois, United States
Illinois CancerCare-Canton
Status: Recruiting
Contact: James L. Wade - 217-876-4740 - kcheek@dmhhs.org
Canton, Illinois, United States
Memorial Hospital of Carbondale
Status: Recruiting
Contact: James L. Wade - 217-876-4740 - kcheek@dmhhs.org
Carbondale, Illinois, United States
Illinois CancerCare-Carthage
Status: Recruiting
Contact: James L. Wade - 217-876-4740 - kcheek@dmhhs.org
Carthage, Illinois, United States
Centralia Oncology Clinic
Status: Recruiting
Contact: James L. Wade - 217-876-4740 - kcheek@dmhhs.org
Centralia, Illinois, United States
Cancer Care Center of Decatur
Status: Recruiting
Contact: James L. Wade - 217-876-4740 - kcheek@dmhhs.org
Decatur, Illinois, United States
Central Illinois CCOP
Status: Recruiting
Contact: James L. Wade - 217-876-4740 - kcheek@dmhhs.org
Decatur, Illinois, United States
Decatur Memorial Hospital
Status: Recruiting
Contact: Anne S. Tsao - 713-792-6363
Decatur, Illinois, United States
Crossroads Cancer Center
Status: Recruiting
Contact: James L. Wade - 217-876-4740 - kcheek@dmhhs.org
Effingham, Illinois, United States
Illinois CancerCare-Eureka
Status: Recruiting
Contact: James L. Wade - 217-876-4740 - kcheek@dmhhs.org
Eureka, Illinois, United States
Illinois CancerCare Galesburg
Status: Recruiting
Contact: James L. Wade - 217-876-4740 - kcheek@dmhhs.org
Galesburg, Illinois, United States
Western Illinois Cancer Treatment Center
Status: Recruiting
Contact: James L. Wade - 217-876-4740 - kcheek@dmhhs.org
Galesburg, Illinois, United States
Illinois CancerCare-Kewanee Clinic
Status: Recruiting
Contact: James L. Wade - 217-876-4740 - kcheek@dmhhs.org
Kewanee, Illinois, United States
Illinois CancerCare-Macomb
Status: Recruiting
Contact: James L. Wade - 217-876-4740 - kcheek@dmhhs.org
Macomb, Illinois, United States
Illinois CancerCare-Ottawa Clinic
Status: Recruiting
Contact: James L. Wade - 217-876-4740 - kcheek@dmhhs.org
Ottawa, Illinois, United States
Radiation Oncology of Northern Illinois
Status: Recruiting
Contact: James L. Wade - 217-876-4740 - kcheek@dmhhs.org
Ottawa, Illinois, United States
Illinois CancerCare-Pekin
Status: Recruiting
Contact: James L. Wade - 217-876-4740 - kcheek@dmhhs.org
Pekin, Illinois, United States
Pekin Cancer Treatment Center
Status: Recruiting
Contact: James L. Wade - 217-876-4740 - kcheek@dmhhs.org
Pekin, Illinois, United States
Illinois CancerCare-Peoria
Status: Recruiting
Contact: James L. Wade - 217-876-4740 - kcheek@dmhhs.org
Peoria, Illinois, United States
Methodist Medical Center of Illinois
Status: Recruiting
Contact: James L. Wade - 217-876-4740 - kcheek@dmhhs.org
Peoria, Illinois, United States
OSF Saint Francis Medical Center
Status: Recruiting
Contact: James L. Wade - 217-876-4740 - kcheek@dmhhs.org
Peoria, Illinois, United States
OSF Saint Francis Medical Center Radiation Oncology Service at the Central Illinois Comprehensive CC
Status: Recruiting
Contact: James L. Wade - 217-876-4740 - kcheek@dmhhs.org
Peoria, Illinois, United States
Illinois CancerCare-Peru
Status: Recruiting
Contact: James L. Wade - 217-876-4740 - kcheek@dmhhs.org
Peru, Illinois, United States
Valley Radiation Oncology
Status: Recruiting
Contact: James L. Wade - 217-876-4740 - kcheek@dmhhs.org
Peru, Illinois, United States
Illinois CancerCare-Princeton
Status: Recruiting
Contact: James L. Wade - 217-876-4740 - kcheek@dmhhs.org
Princeton, Illinois, United States
Central Illinois Hematology Oncology Center
Status: Recruiting
Contact: James L. Wade - 217-876-4740 - kcheek@dmhhs.org
Springfield, Illinois, United States
Memorial Medical Center
Status: Recruiting
Contact: James L. Wade - 217-876-4740 - kcheek@dmhhs.org
Springfield, Illinois, United States
Southern Illinois University School of Medicine
Status: Recruiting
Contact: James L. Wade - 217-876-4740 - kcheek@dmhhs.org
Springfield, Illinois, United States
Springfield Clinic
Status: Recruiting
Contact: James L. Wade - 217-876-4740 - kcheek@dmhhs.org
Springfield, Illinois, United States
Cancer Care Specialists of Illinois-Swansea
Status: Recruiting
Contact: James L. Wade - 217-876-4740 - kcheek@dmhhs.org
Swansea, Illinois, United States
Franciscan St. Francis Health-Beech Grove
Status: Recruiting
Contact: James L. Wade - 217-876-4740 - kcheek@dmhhs.org
Beech Grove, Indiana, United States
Franciscan Saint Francis Health-Indianapolis
Status: Withdrawn
Indianapolis, Indiana, United States
Reid Hospital and Health Care Services
Status: Withdrawn
Richmond, Indiana, United States
Oncology Hematology Care Inc-Crestview
Status: Active, not recruiting
Crestview Hills, Kentucky, United States
University of Kentucky/Markey Cancer Center
Status: Active, not recruiting
Lexington, Kentucky, United States
Michigan Cancer Research Consortium CCOP
Status: Withdrawn
Ann Arbor, Michigan, United States
Saint Joseph Mercy Hospital
Status: Terminated
Ann Arbor, Michigan, United States
University of Michigan Comprehensive Cancer Center
Status: Recruiting
Contact: Philip J. Stella - 734-712-4673
Ann Arbor, Michigan, United States
Oakwood Hospital and Medical Center
Status: Recruiting
Contact: Anne S. Tsao - 713-792-6363
Dearborn, Michigan, United States
Henry Ford Hospital
Status: Recruiting
Contact: Philip J. Stella - 734-712-4673
Detroit, Michigan, United States
Saint John Hospital and Medical Center
Status: Recruiting
Contact: Robert A. Chapman - 313-916-1784
Detroit, Michigan, United States
Wayne State University/Karmanos Cancer Institute
Status: Recruiting
Contact: Philip J. Stella - 734-712-4673
Detroit, Michigan, United States
Weisberg Cancer Treatment Center
Status: Recruiting
Contact: Shirish M. Gadgeel - 313-576-9363
Farmington Hills, Michigan, United States
Genesys Hurley Cancer Institute
Status: Recruiting
Contact: Shirish M. Gadgeel - 313-576-9363
Flint, Michigan, United States
Genesys Regional Medical Center-West Flint Campus
Status: Recruiting
Contact: Philip J. Stella - 734-712-4673
Flint, Michigan, United States
Hurley Medical Center
Status: Withdrawn
Flint, Michigan, United States
Allegiance Health
Status: Recruiting
Contact: Philip J. Stella - 734-712-4673
Jackson, Michigan, United States
Sparrow Hospital
Status: Recruiting
Contact: Philip J. Stella - 734-712-4673
Lansing, Michigan, United States
Saint Mary Mercy Hospital
Status: Recruiting
Contact: Philip J. Stella - 734-712-4673
Livonia, Michigan, United States
Saint Joseph Mercy Oakland
Status: Recruiting
Contact: Philip J. Stella - 734-712-4673
Pontiac, Michigan, United States
Saint Joseph Mercy Port Huron
Status: Recruiting
Contact: Philip J. Stella - 734-712-4673
Port Huron, Michigan, United States
Saint Mary's of Michigan
Status: Recruiting
Contact: Philip J. Stella - 734-712-4673
Saginaw, Michigan, United States
Saint John Macomb-Oakland Hospital
Status: Recruiting
Contact: Philip J. Stella - 734-712-4673
Warren, Michigan, United States
Singing River Hospital
Status: Recruiting
Contact: Philip J. Stella - 734-712-4673
Pascagoula, Mississippi, United States
Parkland Health Center-Bonne Terre
Status: Recruiting
Contact: James E. Clarkson - 228-809-5292
Bonne Terre, Missouri, United States
Saint Francis Medical Center
Status: Recruiting
Contact: James L. Wade - 217-876-4740 - kcheek@dmhhs.org
Cape Girardeau, Missouri, United States
Southeast Cancer Center
Status: Recruiting
Contact: James L. Wade - 217-876-4740 - kcheek@dmhhs.org
Cape Girardeau, Missouri, United States
Capital Region Medical Center-Goldschmidt Cancer Center
Status: Recruiting
Contact: James L. Wade - 217-876-4740 - kcheek@dmhhs.org
Jefferson City, Missouri, United States
Missouri Baptist Medical Center
Status: Recruiting
Contact: James L. Wade - 217-876-4740 - kcheek@dmhhs.org
Saint Louis, Missouri, United States
Sainte Genevieve County Memorial Hospital
Status: Recruiting
Contact: James L. Wade - 217-876-4740 - kcheek@dmhhs.org
Sainte Genevieve, Missouri, United States
Missouri Baptist Sullivan Hospital
Status: Recruiting
Contact: James L. Wade - 217-876-4740 - kcheek@dmhhs.org
Sullivan, Missouri, United States
Missouri Baptist Outpatient Center-Sunset Hills
Status: Recruiting
Contact: James L. Wade - 217-876-4740 - kcheek@dmhhs.org
Sunset Hills, Missouri, United States
Billings Clinic Cancer Center
Status: Recruiting
Contact: James L. Wade - 217-876-4740 - kcheek@dmhhs.org
Billings, Montana, United States
Frontier Cancer Center and Blood Institute-Billings
Status: Recruiting
Contact: Benjamin T. Marchello - 800-648-6274
Billings, Montana, United States
Montana Cancer Consortium CCOP
Status: Terminated
Billings, Montana, United States
Saint Vincent Healthcare
Status: Recruiting
Contact: Benjamin T. Marchello - 800-648-6274
Billings, Montana, United States
Bozeman Deaconess Cancer Center
Status: Recruiting
Contact: Benjamin T. Marchello - 800-648-6274
Bozeman, Montana, United States
Bozeman Deaconess Hospital
Status: Withdrawn
Bozeman, Montana, United States
Saint James Community Hospital and Cancer Treatment Center
Status: Recruiting
Contact: Benjamin T. Marchello - 800-648-6274
Butte, Montana, United States
Benefis Healthcare- Sletten Cancer Institute
Status: Recruiting
Contact: Benjamin T. Marchello - 800-648-6274
Great Falls, Montana, United States
Great Falls Clinic
Status: Recruiting
Contact: Benjamin T. Marchello - 800-648-6274
Great Falls, Montana, United States
Saint Peter's Community Hospital
Status: Terminated
Helena, Montana, United States
Glacier Oncology PLLC
Status: Recruiting
Contact: Benjamin T. Marchello - 800-648-6274
Kalispell, Montana, United States
Kalispell Regional Medical Center
Status: Terminated
Kalispell, Montana, United States
Community Medical Hospital
Status: Recruiting
Contact: Benjamin T. Marchello - 800-648-6274
Missoula, Montana, United States
Montana Cancer Specialists
Status: Recruiting
Contact: Benjamin T. Marchello - 800-648-6274
Missoula, Montana, United States
Saint Patrick Hospital - Community Hospital
Status: Terminated
Missoula, Montana, United States
Carolina Surgical Clinic of Charlotte PA
Status: Recruiting
Contact: Benjamin T. Marchello - 800-648-6274
Charlotte, North Carolina, United States
Novant Health Presbyterian Medical Center
Status: Recruiting
Contact: Justin P. Favaro - 704-384-5369
Charlotte, North Carolina, United States
Oncology Specialists of Charlotte
Status: Recruiting
Contact: Justin P. Favaro - 704-384-5369
Charlotte, North Carolina, United States
Southern Oncology Specialists-Charlotte
Status: Recruiting
Contact: Justin P. Favaro - 704-384-5369
Charlotte, North Carolina, United States
Hendersonville Hematology and Oncology at Pardee
Status: Recruiting
Contact: Justin P. Favaro - 704-384-5369
Hendersonville, North Carolina, United States
Margaret R Pardee Memorial Hospital
Status: Recruiting
Contact: James E. Radford - 828-696-4716
Hendersonville, North Carolina, United States
Lake Norman Hematology Oncology Specialists-Huntersville
Status: Recruiting
Contact: James E. Radford - 828-696-4716
Huntersville, North Carolina, United States
Southern Oncology Specialists-Huntersville
Status: Recruiting
Contact: Justin P. Favaro - 704-384-5369
Huntersville, North Carolina, United States
Matthews Radiation Oncology Center
Status: Recruiting
Contact: Justin P. Favaro - 704-384-5369
Matthews, North Carolina, United States
Novant Health Cancer Specialists-Matthews
Status: Recruiting
Contact: Justin P. Favaro - 704-384-5369
Matthews, North Carolina, United States
Lake Norman Hematology Oncology Specialists-Mooresville
Status: Recruiting
Contact: Justin P. Favaro - 704-384-5369
Mooresville, North Carolina, United States
Iredell Memorial Hospital
Status: Recruiting
Contact: Justin P. Favaro - 704-384-5369
Statesville, North Carolina, United States
Southeast Cancer Control Consortium CCOP
Status: Recruiting
Contact: Ruby A. Grimm - 704-873-5661
Winston-Salem, North Carolina, United States
Strecker Cancer Center-Belpre
Status: Recruiting
Contact: Anne S. Tsao - 713-792-6363
Belpre, Ohio, United States
Adena Regional Medical Center
Status: Recruiting
Contact: John P. Kuebler - 614-566-3275
Chillicothe, Ohio, United States
Oncology Hematology Care Inc - Anderson
Status: Recruiting
Contact: John P. Kuebler - 614-566-3275
Cincinnati, Ohio, United States
Oncology Hematology Care Inc - Kenwood
Status: Active, not recruiting
Cincinnati, Ohio, United States
Oncology Hematology Care Inc-Blue Ash
Status: Active, not recruiting
Cincinnati, Ohio, United States
Oncology Hematology Care Inc-Eden Park
Status: Active, not recruiting
Cincinnati, Ohio, United States
Oncology Hematology Care Inc-Mercy West
Status: Active, not recruiting
Cincinnati, Ohio, United States
Columbus CCOP
Status: Active, not recruiting
Columbus, Ohio, United States
Columbus Oncology and Hematology Associates Inc
Status: Terminated
Columbus, Ohio, United States
Doctors Hospital
Status: Recruiting
Contact: John P. Kuebler - 614-566-3275
Columbus, Ohio, United States
Grant Medical Center
Status: Recruiting
Contact: John P. Kuebler - 614-566-3275
Columbus, Ohio, United States
Mount Carmel Health Center West
Status: Recruiting
Contact: John P. Kuebler - 614-566-3275
Columbus, Ohio, United States
Riverside Methodist Hospital
Status: Recruiting
Contact: John P. Kuebler - 614-566-3275
Columbus, Ohio, United States
The Mark H Zangmeister Center
Status: Recruiting
Contact: John P. Kuebler - 614-566-3275
Columbus, Ohio, United States
Dayton CCOP
Status: Recruiting
Contact: John P. Kuebler - 800-446-5532
Dayton, Ohio, United States
Good Samaritan Hospital - Dayton
Status: Terminated
Dayton, Ohio, United States
Grandview Hospital
Status: Active, not recruiting
Dayton, Ohio, United States
Miami Valley Hospital
Status: Terminated
Dayton, Ohio, United States
Samaritan North Health Center
Status: Active, not recruiting
Dayton, Ohio, United States
Delaware Health Center-Grady Cancer Center
Status: Active, not recruiting
Delaware, Ohio, United States
Delaware Radiation Oncology
Status: Recruiting
Contact: John P. Kuebler - 614-566-3275
Delaware, Ohio, United States
Grady Memorial Hospital
Status: Recruiting
Contact: John P. Kuebler - 614-566-3275
Delaware, Ohio, United States
Oncology Hematology Care Inc-Healthplex
Status: Recruiting
Contact: John P. Kuebler - 614-566-3275
Fairfield, Ohio, United States
Blanchard Valley Hospital
Status: Active, not recruiting
Findlay, Ohio, United States
Atrium Medical Center-Middletown Regional Hospital
Status: Active, not recruiting
Franklin, Ohio, United States
Wayne Hospital
Status: Active, not recruiting
Greenville, Ohio, United States
Kettering Medical Center
Status: Active, not recruiting
Kettering, Ohio, United States
Fairfield Medical Center
Status: Active, not recruiting
Lancaster, Ohio, United States
Marietta Memorial Hospital
Status: Recruiting
Contact: John P. Kuebler - 614-566-3275
Marietta, Ohio, United States
Knox Community Hospital
Status: Recruiting
Contact: John P. Kuebler - 614-566-3275
Mount Vernon, Ohio, United States
Licking Memorial Hospital
Status: Recruiting
Contact: John P. Kuebler - 614-566-3275
Newark, Ohio, United States
Newark Radiation Oncology
Status: Recruiting
Contact: John P. Kuebler - 614-566-3275
Newark, Ohio, United States
Southern Ohio Medical Center
Status: Recruiting
Contact: John P. Kuebler - 614-566-3275
Portsmouth, Ohio, United States
Springfield Regional Medical Center
Status: Recruiting
Contact: John P. Kuebler - 614-566-3275
Springfield, Ohio, United States
Upper Valley Medical Center
Status: Recruiting
Contact: John P. Kuebler - 614-488-2745 - sheree@columbusccop.org
Troy, Ohio, United States
Saint Ann's Hospital
Status: Active, not recruiting
Westerville, Ohio, United States
Greene Memorial Hospital
Status: Recruiting
Contact: John P. Kuebler - 614-566-3275
Xenia, Ohio, United States
Genesis HealthCare System
Status: Terminated
Zanesville, Ohio, United States
Clackamas Radiation Oncology Center
Status: Recruiting
Contact: John P. Kuebler - 614-488-2745 - sheree@columbusccop.org
Clackamas, Oregon, United States
Providence Milwaukie Hospital
Status: Active, not recruiting
Milwaukie, Oregon, United States
Providence Newberg Medical Center
Status: Terminated
Newberg, Oregon, United States
Providence Willamette Falls Medical Center
Status: Active, not recruiting
Oregon City, Oregon, United States
Providence Portland Medical Center
Status: Active, not recruiting
Portland, Oregon, United States
Providence Saint Vincent Medical Center
Status: Recruiting
Contact: Keith S. Lanier - 503-215-6412
Portland, Oregon, United States
SWOG
Status: Active, not recruiting
Portland, Oregon, United States
Western Oncology Research Consortium
Status: Recruiting
Contact: Anne S. Tsao - astsao@mdanderson.org
Portland, Oregon, United States
Greenville Health System Cancer Institute-Easley
Status: Terminated
Easley, South Carolina, United States
Greenville Health System Cancer Institute-Andrews
Status: Recruiting
Contact: Jeffrey K. Giguere - 864-241-6251
Greenville, South Carolina, United States
Greenville Health System Cancer Institute-Butternut
Status: Recruiting
Contact: Jeffrey K. Giguere - 864-241-6251
Greenville, South Carolina, United States
Greenville Health System Cancer Institute-Eastside
Status: Recruiting
Contact: Jeffrey K. Giguere - 864-241-6251
Greenville, South Carolina, United States
Greenville Health System Cancer Institute-Faris
Status: Recruiting
Contact: Jeffrey K. Giguere - 864-241-6251
Greenville, South Carolina, United States
Greenville Memorial Hospital
Status: Recruiting
Contact: Jeffrey K. Giguere - 864-241-6251
Greenville, South Carolina, United States
Cancer Centers of the Carolinas-Greer Medical Oncology
Status: Recruiting
Contact: Jeffrey K. Giguere - 864-241-6251
Greer, South Carolina, United States
Greenville Health System Cancer Institute-Greer
Status: Withdrawn
Greer, South Carolina, United States
Greenville Health System Cancer Institute-Seneca
Status: Recruiting
Contact: Jeffrey K. Giguere - 864-241-6251
Seneca, South Carolina, United States
Greenville Health System Cancer Institute-Spartanburg
Status: Recruiting
Contact: Jeffrey K. Giguere - 864-241-6251
Spartanburg, South Carolina, United States
Wellmont Medical Associates Oncology and Hematology-Bristol
Status: Recruiting
Contact: Jeffrey K. Giguere - 864-241-6251
Bristol, Tennessee, United States
Wellmont Holston Valley Hospital and Medical Center
Status: Active, not recruiting
Kingsport, Tennessee, United States
Wellmont Medical Associates Oncology and Hematology-Kingsport
Status: Recruiting
Contact: Asheesh Shipstone - 423-578-8538
Kingsport, Tennessee, United States
M D Anderson Cancer Center
Status: Recruiting
Contact: Asheesh Shipstone - 423-578-8538
Houston, Texas, United States
M D Anderson Cancer Center
Status: Recruiting
Contact: Anne S. Tsao - 713-792-3245
Houston, Texas, United States
Southwest Oncology Group (SWOG) Research Base
Status: Active, not recruiting
San Antonio, Texas, United States
Danville Hematology Oncology
Status: Recruiting
Contact: Anne S. Tsao - astsao@mdanderson.org
Danville, Virginia, United States
Danville Regional Medical Center
Status: Recruiting
Contact: Qiwei W. Gai - 434-793-0044
Danville, Virginia, United States
Southwest VA Regional Cancer Center
Status: Recruiting
Contact: Timothy W. Brotherton - 434-793-0044
Norton, Virginia, United States
Cancer Care Center at Island Hospital
Status: Recruiting
Contact: Asheesh Shipstone - 423-578-8538
Anacortes, Washington, United States
PeaceHealth Saint Joseph Medical Center
Status: Active, not recruiting
Bellingham, Washington, United States
Harrison HealthPartners Hematology and Oncology-Bremerton
Status: Active, not recruiting
Bremerton, Washington, United States
Highline Medical Center-Main Campus
Status: Active, not recruiting
Burien, Washington, United States
Swedish Medical Center-Edmonds
Status: Active, not recruiting
Edmonds, Washington, United States
Swedish Cancer Institute-Issaquah
Status: Active, not recruiting
Issaquah, Washington, United States
Kadlec Clinic Hematology and Oncology
Status: Active, not recruiting
Kennewick, Washington, United States
Seattle Cancer Care Alliance at EvergreenHealth
Status: Active, not recruiting
Kirkland, Washington, United States
Saint John Medical Center
Status: Active, not recruiting
Longview, Washington, United States
Skagit Valley Hospital
Status: Active, not recruiting
Mount Vernon, Washington, United States
Harrison HealthPartners Hematology and Oncology-Poulsbo
Status: Active, not recruiting
Poulsbo, Washington, United States
Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium
Status: Active, not recruiting
Seattle, Washington, United States
Group Health Cooperative-Seattle
Status: Active, not recruiting
Seattle, Washington, United States
Harborview Medical Center
Status: Active, not recruiting
Seattle, Washington, United States
Minor and James Medical PLLC
Status: Terminated
Seattle, Washington, United States
Swedish Medical Center-Ballard Campus
Status: Active, not recruiting
Seattle, Washington, United States
Swedish Medical Center-First Hill
Status: Active, not recruiting
Seattle, Washington, United States
The Polyclinic
Status: Active, not recruiting
Seattle, Washington, United States
University of Washington Medical Center
Status: Terminated
Seattle, Washington, United States
United General Hospital
Status: Active, not recruiting
Sedro-Woolley, Washington, United States
Cancer Care Northwest - Spokane South
Status: Terminated
Spokane, Washington, United States
Evergreen Hematology and Oncology PS
Status: Active, not recruiting
Spokane, Washington, United States
Rockwood Clinic
Status: Active, not recruiting
Spokane, Washington, United States
Compass Oncology Vancouver
Status: Terminated
Vancouver, Washington, United States
PeaceHealth Southwest Medical Center
Status: Terminated
Vancouver, Washington, United States
Wenatchee Valley Hospital and Clinics
Status: Active, not recruiting
Wenatchee, Washington, United States
Rocky Mountain Oncology
Status: Active, not recruiting
Casper, Wyoming, United States
Big Horn Basin Cancer Center
Status: Terminated
Cody, Wyoming, United States
Billings Clinic-Cody
Status: Recruiting
Contact: Benjamin T. Marchello - 800-648-6274
Cody, Wyoming, United States
Welch Cancer Center
Status: Recruiting
Contact: Benjamin T. Marchello - 800-648-6274
Sheridan, Wyoming, United States
Status: Recruiting
Contact: Benjamin T. Marchello - 800-648-6274
Start Date
March 2010
Sponsors
National Cancer Institute (NCI)
Source
National Cancer Institute (NCI)
Record processing date
ClinicalTrials.gov processed this data on July 28, 2015
ClinicalTrials.gov page